Pharmaphorum
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
Pharmaphorum
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
Pharmaphorum
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.